Literature DB >> 18258053

WU polyomavirus in children, Canada.

Yacine Abed1, David Wang, Guy Boivin.   

Abstract

WU polyomavirus was detected in nasopharyngeal aspirates in 2 (2.5%) of 79 children with respiratory infections (both infected with respiratory syncytial virus) and in 5 (6.4%) of 78 asymptomatic children during the same winter season in Canada. The strains were closely related to Australian and American viruses based on analysis of large T antigen (TAg) and VP2 genes. The pathogenic role of WU virus is still uncertain.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18258053      PMCID: PMC2876769          DOI: 10.3201/eid1312.070909

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


Polyomaviruses are nonenveloped viruses that have an icosahedral capsid containing a small, circular, double-stranded DNA genome (). These viruses have been identified in a variety of mammals and birds worldwide, and the most studied polyomavirus species infecting animals are the mouse polyomavirus () and the simian vacuolating (SV40) virus (). In 1971, 2 human polyomavirus species named BK and JC viruses, respectively, were first isolated from the urine of a kidney allograft recipient with chronic pyelonephritis and advanced renal failure () and from the brain of a patient with progressive multifocal leukoencephalopathy (). Recently, 2 new human polyomavirus members were described. The KI virus was identified in nasopharyngeal aspirates (NPA) and feces from patients with respiratory tract infections in Sweden (). Also, Gaynor and colleagues () reported the detection and molecular characterization of the WU virus in clinical respiratory samples from patients with acute respiratory tract infections (ARTI). Although the pathogenesis of BK and JC viruses has been clearly established, the role of the KI and WU viruses as respiratory pathogens has yet to be demonstrated. In this article, we report on the molecular detection and characterization of WU viruses in NPA from hospitalized children with or without respiratory tract infections.

The Study

We tested 157 NPA specimens obtained from a case-control study on the incidence of respiratory viral agents, the results of which have been partly reported by our group (). Participants were children <3 years of age who were hospitalized from December 2002 through April 2003 at Laval University Hospital Center in Quebec City, Quebec, Canada. Case-patients were children admitted for ARTI (mostly bronchiolitis, pneumonitis, and laryngotracheobronchitis) who had an NPA collected as part of the investigation of their illness. A research nurse administered a specific questionnaire at admission in the presence of the parents. At the end of the hospitalization, the children’s charts were reviewed to collect clinical and laboratory data. Eligible controls were children hospitalized during the same period for any elective surgery. These children had no concomitant respiratory symptoms or fever at admission, although they might have had an ARTI in the weeks before hospitalization. The study nurse obtained a signed consent from parents and a NPA was obtained during surgery. The original study was approved by the ethics committee of the Center Hospitalier Universitaire de Quebec. NPA samples (200 μL) were used for nucleic acid extraction using the QIAamp viral RNA Mini Kit (QIAGEN, Inc., Mississauga, Ontario, Canada), which has been shown to recover both RNA and DNA. These specimens were previously analyzed by using a multiplex real-time RT-PCR assay for influenza A and B viruses, human respiratory syncytial virus (hRSV), and human metapneumovirus (hMPV) (). For symptomatic children, viral cultures and antigen detection assays were performed at the treating physician’s request. The specimens were frozen at –80°C during the 4 years before PCR studies began for WU polyomavirus. All specimens were first tested for WU virus DNA by using primers AG0048 and AG0049, which allowed the amplification of a 244-bp product in the 3′ end of the large T antigen (TAg) region (). A plasmid containing the partial WU genomic DNA from the original Australian virus (B0 strain) served as the positive control in each PCR batch (). For WU-positive samples with the TAg primers, a confirmatory PCR assay was performed with primers AG0044 and AG0045 to amplify a 250-bp fragment from the VP2 region (). PCR products were analyzed by agarose gel electrophoresis. Positive amplicons were subsequently purified and sequenced by using the respective PCR primers. The Canadian WU VP2 sequences were compared with those of 18 WU viruses that originated in Brisbane, Queensland, Australia, and St Louis, Missouri, USA (). For this purpose, multiple nucleotide sequence alignments were performed by using the ClustalW program followed by phylogenetic analyses, which were conducted with the MEGA version 3.1 software using the neighbor-joining algorithm with Kimura-2 parameters (). By using the PCR assay with primers targeting the large TAg, WU sequences were detected in 2 (2.53%) of 79 symptomatic children (the 2 children were 13 months old) and in 5 (6.41%) of 78 asymptomatic children, 13–24 months of age (mean age 20 months) (Table). Symptomatic children had a diagnosis of bronchiolitis (patient 1) and pneumonitis (patient 2) and were both coinfected with hRSV. In contrast, no other viruses were detected in the asymptomatic children who underwent elective surgery. The duration of hospitalization for the 2 symptomatic children with dual WU/hRSV infection (3 and 4 days) was similar to that of 120 children with single hRSV infection (median: 4 days). By using the PCR assay with primers targeting the VP2 region, WU sequences were detected in 4/7 previously positive children, including 1 symptomatic (patient 1) and 3 asymptomatic (patients 3, 5 and 6) patients (Table). The 7 large TAg nt sequences of Canadian WU viruses were 100% identical and had 99.5% identity to the WU sequence contained in the control plasmid from Australia (data not shown). In addition, 100% identity was found between the VP2 nt sequences of the 4 Canadian WU viruses (data not shown). The latter also shared 100% identity with the most frequently observed WU genotypes (represented by previously-reported WU strains B9, S6, B28, B37, B22, B24, B35, B10, B1, and B17 [GenBank accession numbers: EF444592, EF444593, EF444590, EF444589, EF444588, EF444587, EF444586, EF444584, EF444583 and EF444582, respectively]) and, obviously, clustered together in the phylogenetic tree (Figure).
Table

Clinical data from 7 WU polyomavirus–infected children, Canada, 2003*

Patient no.SexAge, moDate sample collectedSample typePCR for WU virus LTAg/VP2DiagnosisCopathogen
1F13Feb 13NPA+/+BronchiolitishRSV
2M13Mar 5NPA+/–PneumonitishRSV
3F13Feb 24NPA+/+None†None
4M20Mar 13NPA+/–None†None
5F24Mar 17NPA+/+None†None
6M19Mar 31NPA+/+None†None
7F24Apr 1NPA+/–None†None

*NPA, nasopharyngeal aspirates; hRSV, human respiratory syncytial virus.
†No fever or respiratory symptoms at the time of elective surgery.

Figure

Phylogenetic analysis of Canadian WU polyomavirus strains CanWUT9–2003, CanWUT38–2003, CanWUC40–2003 and CanWUT52–2003 (shown in boldface), based on nucleotide sequences of the VP2 region. Multiple nucleotide sequence alignments were performed by using the ClustalW program and a phylogenetic tree was constructed with the MEGA 3.1 software using the neighbor-joining algorithm with Kimura-2 parameters (). The analysis included WU strains previously identified from Australian and American cohorts () i.e., B9, S6, B28, B37, B22, B24, B35, B10, B1, B17, B0, B12, B20, B14, B34, B21, B3, and B2 (GenBank accession nos.: EF444592, EF444593, EF444590, EF444589, EF444588, EF444587, EF444586, EF444584, EF444583, EF444582, EF-444555, EF444557, EF444561, EF444562, EF444572, EF444585, EF444567, and EF444591, respectively).

*NPA, nasopharyngeal aspirates; hRSV, human respiratory syncytial virus.
†No fever or respiratory symptoms at the time of elective surgery. Phylogenetic analysis of Canadian WU polyomavirus strains CanWUT9–2003, CanWUT38–2003, CanWUC40–2003 and CanWUT52–2003 (shown in boldface), based on nucleotide sequences of the VP2 region. Multiple nucleotide sequence alignments were performed by using the ClustalW program and a phylogenetic tree was constructed with the MEGA 3.1 software using the neighbor-joining algorithm with Kimura-2 parameters (). The analysis included WU strains previously identified from Australian and American cohorts () i.e., B9, S6, B28, B37, B22, B24, B35, B10, B1, B17, B0, B12, B20, B14, B34, B21, B3, and B2 (GenBank accession nos.: EF444592, EF444593, EF444590, EF444589, EF444588, EF444587, EF444586, EF444584, EF444583, EF444582, EF-444555, EF444557, EF444561, EF444562, EF444572, EF444585, EF444567, and EF444591, respectively).

Conclusions

In this study, we report for the first time, to our knowledge, the presence of the newly described WU polyomavirus in Canadian children. We found that more asymptomatic (6.4%) than symptomatic (2.5%) children shed viral DNA in their respiratory tract. The WU polyomavirus was previously identified in respiratory tract samples from Australian and American patients, which suggests its worldwide distribution. Efforts to culture this new virus by using PCR-positive respiratory specimens have thus far been unsuccessful (D. Wang, unpub. data). The 7 sequences of the large TAg region and the 4 sequences of the VP2 region from the Canadian WU strains displayed no sequence variations. This could be due to the short size of these PCR products (244 and 250 bp, respectively) and the stability of this double-stranded DNA genome. A similar finding of limited sequence variation was reported in the previous molecular study performed with Australian and American WU strains (). Indeed, 4 Canadian WU strains had 100% nucleotide identity with 10 strains selected from these cohorts when VP2 sequences were compared (Figure). Since we aimed at evaluating the possible contribution of the WU polyomavirus in respiratory tract infections of children, we tested NPA samples from symptomatic and asymptomatic subjects of the same age (<3 years) that were collected during the same winter period at the same institution. The WU virus was detected in 5 asymptomatic children at the time of an elective surgery and in 2 symptomatic children (bronchiolitis and pneumonitis) who were also infected with hRSV. A high rate of coinfection was also noted in the Australian cohort (68%) and in the American cohort (100%) (). Notably, similar findings were obtained in a study on the related KI polyomavirus in which another viral pathogen was found in 5/6 KI-positive samples (). By analogy with other human polyomaviruses (BK and JC), WU and KI possibly could establish a latent infection with subsequent asymptomatic reactivation; further studies are needed for confirmation. The presence of WU virus in the control children could also represent prolonged shedding from a prior respiratory tract infection. In conclusion, although this study confirmed the presence of the WU polyomavirus in NPA samples from Canadian children and suggests that its distribution is worldwide, its role in respiratory tract diseases of children remains undetermined.
  8 in total

1.  The vacuolating virus, S.V. 40.

Authors:  B H SWEET; M R HILLEMAN
Journal:  Proc Soc Exp Biol Med       Date:  1960-11

2.  MEGA3: Integrated software for Molecular Evolutionary Genetics Analysis and sequence alignment.

Authors:  Sudhir Kumar; Koichiro Tamura; Masatoshi Nei
Journal:  Brief Bioinform       Date:  2004-06       Impact factor: 11.622

3.  Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy.

Authors:  B L Padgett; D L Walker; G M ZuRhein; R J Eckroade; B H Dessel
Journal:  Lancet       Date:  1971-06-19       Impact factor: 79.321

4.  New human papovavirus (B.K.) isolated from urine after renal transplantation.

Authors:  S D Gardner; A M Field; D V Coleman; B Hulme
Journal:  Lancet       Date:  1971-06-19       Impact factor: 79.321

5.  Neoplasms in mice inoculated with a tumor agent carried in tissue culture.

Authors:  S E STEWART; B E EDDY; N BORGESE
Journal:  J Natl Cancer Inst       Date:  1958-06       Impact factor: 13.506

6.  Identification of a third human polyomavirus.

Authors:  Tobias Allander; Kalle Andreasson; Shawon Gupta; Annelie Bjerkner; Gordana Bogdanovic; Mats A A Persson; Tina Dalianis; Torbjörn Ramqvist; Björn Andersson
Journal:  J Virol       Date:  2007-02-07       Impact factor: 5.103

7.  Human metapneumovirus infections in hospitalized children.

Authors:  Guy Boivin; Gaston De Serres; Stéphanie Côté; Rodica Gilca; Yacine Abed; Louis Rochette; Michel G Bergeron; Pierre Déry
Journal:  Emerg Infect Dis       Date:  2003-06       Impact factor: 6.883

8.  Identification of a novel polyomavirus from patients with acute respiratory tract infections.

Authors:  Anne M Gaynor; Michael D Nissen; David M Whiley; Ian M Mackay; Stephen B Lambert; Guang Wu; Daniel C Brennan; Gregory A Storch; Theo P Sloots; David Wang
Journal:  PLoS Pathog       Date:  2007-05-04       Impact factor: 6.823

  8 in total
  40 in total

1.  Whole-genome characterization and genotyping of global WU polyomavirus strains.

Authors:  Seweryn Bialasiewicz; Rebecca Rockett; David W Whiley; Yacine Abed; Tobias Allander; Michael Binks; Guy Boivin; Allen C Cheng; Ju-Young Chung; Patricia E Ferguson; Nicole M Gilroy; Amanda J Leach; Cecilia Lindau; John W Rossen; Tania C Sorrell; Michael D Nissen; Theo P Sloots
Journal:  J Virol       Date:  2010-03-31       Impact factor: 5.103

Review 2.  Emerging viral diseases.

Authors:  Andrew Pekosz; Gregory E Glass
Journal:  Md Med       Date:  2008

3.  [A molecular epidemiological study of KI polyomavirus and WU polyomavirus in children with acute respiratory infection in Tianjin, China].

Authors:  Shu-Xiang Lin; Wei Wang; Wei Guo; Hong-Jiang Yang; Bai-Cheng Ma; Yu-Lian Fang; Yong-Sheng Xu
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2017-07

4.  Prevalence of human KI and WU polyomaviruses in children with acute respiratory tract infection in China.

Authors:  Xin-hui Yuan; Yu Jin; Zhi-ping Xie; Han-chun Gao; Zi-qian Xu; Li-shu Zheng; Rong-fang Zhang; Jing-rong Song; Yun-de Hou; Zhao-jun Duan
Journal:  J Clin Microbiol       Date:  2008-07-30       Impact factor: 5.948

Review 5.  The role of polyomaviruses in human disease.

Authors:  Mengxi Jiang; Johanna R Abend; Silas F Johnson; Michael J Imperiale
Journal:  Virology       Date:  2008-11-07       Impact factor: 3.616

6.  DNA from BK virus and JC virus and from KI, WU, and MC polyomaviruses as well as from simian virus 40 is not detected in non-UV-light-associated primary malignant melanomas of mucous membranes.

Authors:  Géraldine Giraud; Torbjörn Ramqvist; Boel Ragnarsson-Olding; Tina Dalianis
Journal:  J Clin Microbiol       Date:  2008-09-03       Impact factor: 5.948

7.  Prevalence and pathogenicity of WU and KI polyomaviruses in children, the Netherlands.

Authors:  Marieke M van der Zalm; John W A Rossen; Bart E van Ewijk; Berry Wilbrink; Petra C H M van Esch; Tom F W Wolfs; Cornelis K van der Ent
Journal:  Emerg Infect Dis       Date:  2008-11       Impact factor: 6.883

8.  WU polyomavirus in fecal specimens of children with acute gastroenteritis, China.

Authors:  Lili Ren; Richard Gonzalez; Xiwei Xu; Jianguo Li; Jing Zhang; Guy Vernet; Gláucia Paranhos-Baccalà; Qi Jin; Jianwei Wang
Journal:  Emerg Infect Dis       Date:  2009-01       Impact factor: 6.883

9.  No evidence for WU polyomavirus infection in chronic obstructive pulmonary disease.

Authors:  Felix C Ringshausen; Marei Heckmann; Benedikt Weissbrich; Florian Neske; Irmgard Borg; Umut Knoop; Juliane Kronsbein; Barbara M Hauptmeier; Gerhard Schultze-Werninghaus; Gernot Rohde
Journal:  Infect Agent Cancer       Date:  2009-08-28       Impact factor: 2.965

10.  DNA from KI, WU and Merkel cell polyomaviruses is not detected in childhood central nervous system tumours or neuroblastomas.

Authors:  Géraldine Giraud; Torbjörn Ramqvist; Diana V Pastrana; Vincent Pavot; Cecilia Lindau; Per Kogner; Abiel Orrego; Christopher B Buck; Tobias Allander; Stefan Holm; Bengt Gustavsson; Tina Dalianis
Journal:  PLoS One       Date:  2009-12-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.